<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39442238</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>180</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Therapeutic oligonucleotide ASC1R shows excellent tolerability and remarkable efficacy in reducing SARS-CoV-2 mRNA levels in C57BL/6 mice.</ArticleTitle><Pagination><StartPage>117587</StartPage><MedlinePgn>117587</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2024.117587</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(24)01473-2</ELocationID><Abstract><AbstractText>The coronavirus pandemic has resulted in over 775 million cases and 7 million deaths worldwide, driving efforts to develop therapeutic strategies to control the viral infection. Therapeutic oligonucleotides have shown promise in treating many pathological conditions, including those of viral origin. The present study assessed the in vivo efficacy and safety of ASC1R, a novel therapeutic oligonucleotide of unconventional design targeting the conserved viral RdRp sequence essential for replication. In functional studies, ASC1R was administered to transfected C57BL/6 mice at doses of 1 and 10 mg/kg. Safety assessments included acute toxicity evaluations at doses ranging from 30 to 100 mg/kg, and subacute toxicity evaluations of repeated doses of 1 and 10 mg/kg. Evaluations included general clinical observations, findings at necropsy, measurements of organ weight, and histopathological examinations of the liver, lungs, spleen, and kidneys. ASC1R effectively reduced RdRp levels &gt;94 % within 24 hours following a single 1 mg/kg dose, with no observed organ toxicity. Acute and subacute toxicity assessments found that mice receiving high (≥30 mg/kg) or repeated (10 mg/kg for 7 days) doses of ASC1R showed an increase in relative spleen weight, without histopathological changes. The marked ability of a single low dose of ASC1R (1 mg/kg) to reduce viral RNA suggests its potential for clinical applications, balancing therapeutic efficacy with minimal side effects. Our findings indicate that ASC1R has promise as a viable treatment option for patients with COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nemethova</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Selecta Biotech SE, Bratislava 84107, Slovakia. Electronic address: nemethova@selectabiotech.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babiakova</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Selecta Biotech SE, Bratislava 84107, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selc</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovakia; Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava 84511, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakic</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhelska</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Selecta Biotech SE, Bratislava 84107, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teglasova</LastName><ForeName>Boglarka</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Selecta Biotech SE, Bratislava 84107, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makovicky</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babelova</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovakia; Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava 84511, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razga</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Selecta Biotech SE, Bratislava 84107, Slovakia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ASC1R</Keyword><Keyword MajorTopicYN="N">C57BL/6</Keyword><Keyword MajorTopicYN="N">RdRp</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Therapeutic oligonucleotide</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Selecta Biotech holds the intellectual property rights to ASC1R, with Veronika Nemethova and Filip Razga listed as inventors. Veronika Nemethova and Filip Razga are co-founders and own stock options in Selecta Biotech. The authors have no other conflicts of interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39442238</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2024.117587</ArticleId><ArticleId IdType="pii">S0753-3322(24)01473-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>